[Co-trimoxazole concentration in the prostatic fluid of patients with subacute and chronic prostatitis].
Plasma and prostatic fluid (PF) concentrations of co-trimoxazol (TMP/SMZ) were investigated on 16 patients with subacute or chronic prostatitis. Co-trimoxazol-forte was given perorally, 2X 1 tablet (2X 160 mg TMP/800 mg SMZ), daily. TMP-concentrations in PF were 3.3 micrograms/ml and 2.6 micrograms/ml three and six hours after peroral application (days two and three) respectively. Compared to the concentrations of TMP in plasma, there was an increase by the factor 2.0-3.7. The corresponding concentrations of SMZ in PF were 7.7 micrograms/ml and 10.4 micrograms/ml 3 and 6 hours after medication--i.e. 32% of the plasma concentrations.
D000284:Administration, Oral; D000892:Anti-Infective Agents, Urinary / Q000378:metabolism* / Q000627:therapeutic use; D001682:Biological Availability; D002908:Chronic Disease; D004338:Drug Combinations / Q000378:metabolism / Q000627:therapeutic use; D006801:Humans; D007700:Kinetics; D008297:Male; D011467:Prostate / Q000378:metabolism*; D011472:Prostatitis / Q000188:drug therapy*; D013420:Sulfamethoxazole / Q000378:metabolism* / Q000627:therapeutic use; D014295:Trimethoprim / Q000378:metabolism* / Q000627:therapeutic use; D015662:Trimethoprim, Sulfamethoxazole Drug Combination
D000892:Anti-Infective Agents, Urinary; D004338:Drug Combinations; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D014295:Trimethoprim; D013420:Sulfamethoxazole
Co-trimoxazol-Konzentration im Prostatasekret von Patienten mit subakuter und chronischer Prostatitis.